# Novo Nordisk

Organization · id `cardio:novo-nordisk` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Novo Nordisk A/S; NOVO

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A drug company based in Denmark. It sponsored the SELECT, LEADER and FLOW trials, and it is the applicant listed in the US regulatory records for Ozempic and Wegovy.

## Technical summary

ROR 0435rc536. ClinicalTrials.gov lists Novo Nordisk A/S as lead sponsor of NCT03574597 (SELECT), NCT01179048 (LEADER) and NCT03819153 (FLOW), with sponsor class INDUSTRY. The openFDA application records for NDA209637 and NDA215256 list the applicant as NOVO.

## Connected pages

- Manufactures: Semaglutide injection for diabetes (Ozempic) (`cardio:ozempic`)
- Manufactures: Semaglutide injection for weight management (Wegovy) (`cardio:wegovy`)
- Sponsors: FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease (`cardio:flow-trial`)
- Sponsors: LEADER: liraglutide and cardiovascular events in type 2 diabetes (`cardio:leader-trial`)
- Sponsors: SELECT: semaglutide and cardiovascular outcomes in overweight or obesity (`cardio:select-trial`)

## Provenance

Content hash: 9fd86f8c1b09d73bcd2d6faf64f2d98cb637ee0e0041a83fd26d5c7da6614d51
Last substantive edit: 2026-10-15
Evidence last checked: Not recorded